ClinicalTrials.gg

Program

dibotatug

Also written as “DR-01” and “Dibotatug (DR-01)”.

Its studies are mostly in Anemia, Aplastic · Alopecia Areata · Leukemia, Large Granular Lymphocytic, led by Dren Bio.

Furthest: phase 2, since Jul 21, 20224 company-led studies, 3 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Dren Bio43 open or runningphase 2since Jul 21, 2022Jul 21, 2022Dec 2026phase 2 · NCT05475925

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 21, 2022First study: phase 2 study in Leukemia, Large Granular LymphocyticFirst studyNCT05475925 · 200 planned · United States, Australia, France and more
  2. Sep 16, 2024Phase 1 study in Alopecia AreataNCT06602232 · 81 enrolled · United States, Australia, New Zealand
  3. Jan 4, 2025Phase 1 study in Healthy VolunteerNCT06766864 · 32 enrolled · New Zealand
  4. Jul 14, 2026Phase 2 study in Bone Marrow Failure DisordersNCT07712562 · 60 planned · United States

Ahead

  1. Dec 2026Primary completion: phase 2 study in Leukemia, Large Granular LymphocyticNCT05475925
  2. May 2027Primary completion: phase 1 study in Alopecia AreataNCT06602232
  3. Apr 2029Primary completion: phase 2 study in Bone Marrow Failure DisordersNCT07712562

TargetBeta

KLRD1 →read by rule
“A human non-fucosylated immunoglobulin G1 (IgG1) monoclonal antibody directed against the cell surface receptor and natural killer cell antigen CD94 (killer cell lectin-like receptor D1; KLRD1), ”NCIt, by rule

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07712562Bone Marrow Failure Disorders · United States2RecruitingApr 202960
NCT06766864Healthy Volunteer · New Zealand1CompletedAug 27, 202532
NCT06602232Alopecia Areata · United States, Australia, New Zealand1Active, not recruitingMay 202781
NCT05475925Leukemia, Large Granular Lymphocytic · United States, Australia, France and more2RecruitingDec 2026200

How it is read

Names in the registry

  • “DR-01”, 3 entries
  • “Dibotatug (DR-01)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.